Psoriatic Arthritis News

DESTIN, Fla. — Although the incidence of rheumatologic adverse effects associated with immune checkpoint inhibitors is expected to grow with their increased use, these effects remain poorly studied in random clinical trials, according to findings presented at the 2018 Congress of Clinical Rheumatology.

DESTIN, Fla. — Patients with psoriatic arthritis admitted to the hospital with acute myocardial infarction have significantly higher hospital costs than those without psoriatic arthritis, according to a presenter at the North American Young Rheumatology Investigator Forum.

Patients with spondyloarthritis — particularly men with axial disease — had high rates of drug retention of the first TNF inhibitor over 5- and 10-year time periods, according to findings published in the Journal of Rheumatology.

Apremilast monotherapy improved the signs and symptoms of psoriatic arthritis and was well tolerated among patients with no prior treatment with disease-modifying antirheumatic drugs, according to findings published in Rheumatology.

BOSTON — Bimekizumab, a humanized IgG1 monoclonal antibody that inhibits both interleukin-17F and interleukin-17A, was associated with improved ACR20 response rates in patients with psoriatic arthritis within 2 weeks of first infusion, according to findings from the phase 2b BE ACTIVE study presented here.

BOSTON — Clinical studies indicate that all JAK inhibitors approved so far are effective across a range of immune-mediated inflammatory disorders, with early onset of benefit reported within 1 to 2 weeks, and maximal benefit at 3 months, according to findings presented here.

BOSTON — Several biologic therapies used by rheumatologists, including rituximab, tocilizumab, abatacept and others, can increase the risk for infectious disease in patients, according to findings presented here.

BOSTON — Rheumatologists need to be more aware of the nonplaque aspects and symptoms of psoriasis, in order to better screen and diagnose their patients, according to a presentation at the 2018 Interdisciplinary Autoimmune Summit.

BOSTON — The potential rheumatic side effects of checkpoint inhibitor therapy in patients with cancer can include arthralgia, arthritis, polymyalgia rheumatica, giant cell arteritis, myositis, sicca syndrome and systemic lupus erythematosus, and can be chronic in approximately 50% of patients, according to findings presented here.

BOSTON — Biosimilar competition in Europe has significantly decreased the cost of medication, and has not only increased biosimilar availability but also increased the market share of bio-originators for which there is no biosimilar, according to a speaker at the 2018 Interdisciplinary Autoimmune Summit.